Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1180
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja maintains a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raises the price target from $1040 to $1180.
July 18, 2024 | 3:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Yatin Suneja maintains a Buy rating on Regeneron Pharmaceuticals and raises the price target from $1040 to $1180.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100